Amgen's Q3: Sales Surge, MariTide Promises
Update: 2025-11-05
Description
Amgen's Q3 Results: A Strong Performance Despite ChallengesAmgen, a leading biotechnology company, reported a 12% increase in sales, reaching nearly $9.6 billion, surpassing Wall Street's expectations. The company's adjusted earnings per share also rose by 1%, hitting $5.64. Despite increased spending on experimental weight-loss drug MariTide and a higher tax rate, Amgen raised its financial outlook for the year. Repatha, a cholesterol-lowering drug, saw a 40% sales jump, while Enbrel, an arthritis treatment, experienced a 30% drop due to price reductions. Amgen is making progress with MariTide, expecting key data from mid-stage studies by the end of the year, and has completed enrollment for late-stage studies.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
